唐毅课题组致力于阿尔茨海默病及相关认知障碍疾病的发病机制及早期诊断干预研究，团队主要研究方向包括：

（1）基于动物和人源细胞模型的阿尔茨海默病发病机制研究

    研究免疫、代谢等机制在阿尔茨海默病发病中的作用。

（2）以认知训练和经颅电刺激为代表的非药物干预的早期疗效和神经机制研究

    建立认知障碍疾病新型认知训练方案和经颅电刺激方案，研究其在痴呆前阶段患者和动物模型中的作用机制。

（3）阿尔茨海默病感知觉与认知加工缺陷的特征与机制研究

    从感知觉、睡眠等认知加工过程出发，应用神经电生理和神经影像等技术，探索阿尔茨海默病感知觉与认知加工缺陷的特征与机制。

（4）基于全国多中心队列和社区队列的公卫流病研究

    研究中国认知障碍疾病的流行病学及疾病负担。

国家自然科学基金委员会，重点国际合作项目，82220108009，40Hz经颅交流电刺激对阿尔茨海默病早期干预疗效的神经机制研究，2023/01-2027/12

科学技术部，国家重点研发计划“主动健康和人口老龄化科技应对”重点专项，2022YFC3602600，老年人失能风险的预警与早期防控体系研究，2022/12-2025/11

国家自然科学基金委员会，面上项目，81970996，阿尔茨海默病听觉信息整合障碍的神经机制及其早期诊断作用研究，2020/01-2023/12

北京市自然科学基金委员会，北京杰出青年科学基金项目，JQ19024，胆碱能影像标志物在阿尔茨海默病早期诊断和认知干预评估中的作用研究，2019/11-2022/12

北京市科学技术委员会，首都临床诊疗技术研究及示范应用，Z191100006619046，计算机辅助认知训练早期干预血管性认知障碍技术的优化研究，2019/08-2022/08

科学技术部，国家重点研发计划“重大慢性非传染性疾病防控研究”，2017YFC1310102，阿尔茨海默病痴呆前阶段干预新方法的研究，2017/07-2021/06

国家自然科学基金委员会，面上项目，81671040，胆碱能神经通路在阿尔茨海默病痴呆前阶段及认知训练中的作用机制，2017/01-2020/12

北京市科学技术委员会，首都临床特色应用研究，Z151100004015078，计算机辅助认知训练早期干预阿尔茨海默病痴呆前阶段的随机对照研究，2015/03-2018/09

教育部，留学回国人员科研启动基金，应用家族性AD 患者原代成纤维细胞研究tau 蛋白磷酸化在PS1 Val97Leu突变致病机制中的作用，2010/01-2013/12

北京市自然科学基金委员会，面上项目，7102072，Tau蛋白和自噬在家族性AD发病机制中作用的研究，2010/01-2012/12

国家自然科学基金委员会，青年基金，30900478，应用家族性AD患者原代成纤维细胞研究PS1 Val97Leu突变的发病机制，2010/01-2012/12

一、SCI文章90篇

1.      Qin Q, Qu J, Yin Y, Liang Y, Wang Y, Xie B, Liu Q,Wang X, Xia X, Wang M, Zhang X, Jia J, Xing Y*, Li C*, Tang Y*.Unsupervised machine learning model to predict cognitive impairment insubcortical ischemic vascular disease. Alzheimers Dement. 2023 Feb 14.doi: 10.1002/alz.12971.

2.      Qin Q, Wang M, Li H*, Xu ZD*, Tang Y*.Editorial: The role of microglia in the pathogenesis of neurodegenerativediseases. Front Aging Neurosci. 2023 Jan 6;14:1105896. doi:10.3389/fnagi.2022.1105896. 

3.      Liu PP, Dai SK, Mi TW, Tang GB, Wang Z, Wang H, DuHZ, Tang Y*, Teng Z*, Liu CM*.. Acetate supplementation restorescognitive deficits caused by ARID1A haploinsufficiency in excitatory neurons. EMBOMol Med. 2022;e15795. doi:10.15252/emmm.202215795.

4.      Yu CJ, Wang M, Li RY, Wei T, Yang HC, Yin YS, Mi YX,Qin Q, Tang Y*. TREM2 and Microglia Contribute to the SynapticPlasticity: from Physiology to Pathology. Mol Neurobiol. 2023Feb;60(2):512-523. doi: 10.1007/s12035-022-03100-1.

5.      Xia X, Qin Q, Peng Y, Wang M, Yin Y, Tang Y*.Retinal Examinations Provides Early Warning of Alzheimer's Disease. JAlzheimers Dis. 2022;10.3233/JAD-220596. doi: 10.3233/JAD-220596.

6.      Shi X, Wei T, Hu Y, Wang M, Tang Y*. Theassociations between plasma soluble Trem1 and neurological diseases: aMendelian randomization study. J Neuroinflammation. 2022 Sep6;19(1):218. doi: 10.1186/s12974-022-02582-z.

7.      Lutz MW, Khachaturian AS, Zetterberg H, Blennow K,Willette AA, Mielke MM, Hayden KM, Dodge HH, Tang Y, GreenbergBD, Kukull WA, Khachaturian ZS. Biomarkers of Alzheimer syndrome and relateddementias: A&D author's guide. Alzheimers Dement. 2022Sep;18(9):1595-1601. doi: 10.1002/alz.12772.

8.      Zhang SF, Dai SK, Du HZ, Wang H, Li XG, Tang Y*,Liu CM*. The epigenetic state of EED-Gli3-Gli1 regulatory axis controls embryoniccortical neurogenesis. Stem Cell Reports. 2022 Sep 13;17(9):2064-2080. doi: 10.1016/j.stemcr.2022.07.004.

9.      Yu Y, Lu Y, Wang F, Lu Y, Xie B, Meng X, TangY*. Acanthocytes Identified in Huntington's Disease. Front Neurosci.2022 Jun 6; 16:913401. doi: 10.3389/fnins.2022.913401.

10.   Qin Q, Wang M, Yin Y, Tang Y*. TheSpecific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer'sDisease. Front Immunol. 2022 May 19; 13:845897. doi:10.3389/fimmu.2022.845897.

11.   Wang YY, Deng YS, Dai SK, Mi TW, Li RY, Liu PP, LiuC, HeBD, He XC, Du HZ, Yang HC, Tang Y*, Liu CM*, Teng ZQ*. Lossof microglial EED impairs synapse density, learning and memory. MolPsychiatry. 2022 Jul; 27(7):2999-3009. doi: 10.1038/s41380-022-01576-w.

12.   Li RY, Qin Q, Yang HC, Wang YY, Mi YX, Yin YS, WangM, Yu CJ, Tang Y*. TREM2 in the pathogenesis of AD: a lipid metabolismregulator and potential metabolic therapeutic target. Mol Neurodegener.2022 Jun 3;17(1):40. doi: 10.1186/s13024-022-00542-y.

13.   Wei T, Guo Z, Wang Z, Li C, Zhu W, Zheng Y, Yin Y,Mi Y, Xia X, Hou H, Tang Y*. Five Major Psychiatric Disorders andAlzheimer's Disease: A Bidirectional Mendelian Randomization Study. JAlzheimers Dis. 2022 Mar 31. doi: 10.3233/JAD-220010.

14.   Mi Y, Qin Q, Xing Y, Tang Y*. CapgrasSyndrome as the Core Manifestation of Early-Onset Alzheimer's Disease. JAlzheimers Dis. 2022 Mar 2. doi: 10.3233/JAD-215565.

15.   Temp AGM, Ly A, van Doorn J, Wagenmakers EJ, TangY, Lutz MW, Teipel S. A Bayesian perspective on Biogen's aducanumabtrial. Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12615.

16.   Shenoy SA, Zheng S, Liu W, Dai Y, Liu Y, Hou Z, MoriS, Tang Y, Cheng J, Duan W, Li C. A novel and accuratefull-length HTT mouse model for Huntington's disease. Elife. 2022 Jan13;11:e70217. doi: 10.7554/eLife.70217.

17.   Teipel S, Gustafson D, Ossenkoppele R, Hansson O,Babiloni C, Wagner M, Riedel-Heller S, Kilimann I, Tang Y. Alzheimer'sdisease - standard of diagnosis, treatment, care, and prevention. J Nucl Med.2022 Feb 10:jnumed.121.262239. doi: 10.2967/jnumed.121.262239.

18.   Qin Q, Yin Y, Xing Y, Wang X, Wang Y, Wang F, TangY*. LipidMetabolism in the Development and Progression of Vascular Cognitive Impairment:A Systematic Review. Front Neurol. 2021 Nov 19;12:709134. doi: 10.3389/fneur.2021.709134.

19.   Xing Y, Yang J, Zhou A, Wang F, Tang Y*, Jia J*. Altered brain activity mediates therelationship between white matter hyperintensity severity and cognition inolder adults. Brain Imaging Behav. 2022Apr;16(2):899-908.

20.   Wang C#, Wang Z#, Xie B, Shi X, Yang P, Liu L, Qu T, Qin Q, Xing Y,Zhu W, Teipel SJ, Jia J, Zhao G*, Li L*, Tang Y*. Binaural processing deficit and cognitive impairmentin Alzheimer’s disease. Alzheimers Dement. 2021,DOI: 10.1002/alz.12464.

21.   Wang Z, Zhu W, Xing Y, Jia J, Tang Y*. B vitamins andprevention of cognitive decline and incident dementia: a systematic review andmeta-analysis. Nutr Rev. 2022 Mar 10;80(4):931-949.

22.   Temp AGM, Lutz MW, Trepel D, Tang Y,Wagenmakers EJ, Khachaturian AS, Teipel S. How Bayesian statistics may helpanswer some of the controversial questions in clinical research on Alzheimer'sdisease. Alzheimers Dement. 2021 Jun;17(6):917-919.

23.   Xing Y, Yang J, Zhou A, Wang F, Wei C, Tang Y*,Jia J*. White Matter Fractional Anisotropy Is a Superior Predictor for CognitiveImpairment Than Brain Volumes in Older Adults With Confluent White MatterHyperintensities. Front Psychiatry. 2021, 5;12:633811. doi: 10.3389/fpsyt.2021.633811.eCollection 2021.

24.   Wang F, Ma X, Shi Y, Jia L, Zuo X, Yu Y, Jin H, Tang Y,Guo D, Jia J. Cognitive profiles in adult-onset neuronal intranuclear inclusiondisease: a case series from the memory clinic. Neurol Sci. 2020; doi:10.1007/s10072-020-04864-x.

25.   Wang Z, Yang J, Zhu W, Tang Y*, Jia J. Thesynaptic marker neurogranin as a disease state biomarker in Alzheimer'sdisease: a systematic review and meta-analysis. Int J Neurosci. 2021;10:1-9. doi: 10.1080/00207454.2021.1881087.

26.   Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang Y*.TREM2, microglia, and Alzheimer's disease. Mech Ageing Dev. 2021;195:111438.

27.   Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, Li Y, Li Y, Zhu M,Jiao H, Song Y, Shi Y, Zhang H, Gong M, Wei C, Tang Y, Fang B,Guo D, Wang F, Zhou A, Chu C, Zuo X, Yu Y, Yuan Q, Wang W, Li F, Shi S, Yang H,Zhou C, Liao Z, Lv Y, Li Y, Kan M, Zhao H, Wang S, Yang S, Li H, Liu Z, Wang Q,Qin W, Jia J; COAST Group. Prevalence, risk factors, and management of dementiaand mild cognitive impairment in adults aged 60 years or older in China: across-sectional study. Lancet Public Health. 2020;5(12):e661-e671.

28.   Jia L, Li F, Wei C, Zhu M, Qu Q, Qin W, Tang Y,Shen L, Wang Y, Shen L, Li H, Peng D, Tan L, Luo B, Guo Q, Tang M, Du Y, ZhangJ, Zhang J, Lyu J, Li Y, Zhou A, Wang F, Chu C, Song H, Wu L, Zuo X, Han Y,Liang J, Wang Q, Jin H, Wang W, Lü Y, Li F, Zhou Y, Zhang W, Liao Z, Qiu Q, LiY, Kong C, Li Y, Jiao H, Lu J, Jia J. Prediction of Alzheimer's disease usingmulti-variants from a Chinese genome-wide association study. Brain.2020. doi: 10.1093/brain/awaa364.

29.   Sikkes SAM, Tang Y, Jutten RJ, Wesselman LMP, TurkstraLS, Brodaty H, Clare L, Cassidy-Eagle E, Cox KL, Chételat G, Dautricourt S,Dhana K, Dodge H, Dröes RM, Hampstead BM, Holland T, Lampit A, Laver K, Lutz A,Lautenschlager NT, McCurry SM, Meiland FJM, Morris MC, Mueller KD, Peters R, RidelG, Spector A, van der Steen JT, Tamplin J, Thompson Z; ISTAARTNon-pharmacological Interventions Professional Interest Area, Bahar-Fuchs A.Toward a theory-based specification of non-pharmacological treatments in aging anddementia: Focused reviews and methodological recommendations. AlzheimersDement. 2021;17(2):255-270.

30.   Jia L, Xu H, Chen S, Wang X, Yang J, Gong M, Wei C, TangY, Qu Q, Chu L, Shen L, Zhou C, Wang Q, Zhao T, Zhou A, Li Y, Li F, LiY, Jin H, Qin Q, Jiao H, Li Y, Zhang H, Lyu D, Shi Y, Song Y, Jia J*. The APOEε4 exerts differential effects on familial and other subtypes of Alzheimer'sdisease. Alzheimers Dement. 2020. doi: 10.1002/alz.12153.

31.   Tang Y*, Xing Y, Cui L, Wu C, Wen X, Song H, Wu L, Chang H, Song J, Wang Y*,Zhao G*. Neurology practice during the COVID-19 outbreak and post-pandemic era:experiences and challenges. Eur J Neurol. 2020 Jul 17:10.1111/ene.14445.doi: 10.1111/ene.14445.

32.   Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, Wei C, TangY, Wang Q, Li Y, Li T, Li F, Wang Q, Li Y, Wei Y, Jia J. Bloodneuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomaticstage. Alzheimers Dement. 2021;17(1):49-60.

33.   Qin Q, Yin Y, Wang Y, Lu Y, Tang Y*, Jia J*. Genemutations associated with early onset familial Alzheimer's disease in China: Anoverview and current status. Mol Genet Genomic Med. 2020 Aug 6:e1443.doi: 10.1002/mgg3.1443.

34.   Xing Y, Zhu Z, Du Y, Zhang J, Qu Q, Sun L, Li Y, Guo Y, PengG, Liu Y, Yu Y, Qiao Y, Xie B, Shi X, Lu J, Jia J, Tang Y*. TheEfficacy of COGnitive tRaining in patiEnts with Amnestic mild coGnitiveimpairmENT (COG-REAGENT): Protocol for a Multi-Center Randomized Controlled Trial.J Alzheimers Dis. 2020;75(3):779-787.

35.   Xing Y, Wei P, Wang C, Shan Y, Yu Y, Qiao Y, Xie B, Shi X,Zhu Z, Lu J, Zhao G, Jia J, Tang Y*. TRanscranial AlterNating currentStimulation FOR patients with Mild Alzheimer's Disease (TRANSFORM-AD study):Protocol for a randomized controlled clinical trial. Alzheimers Dement (N Y).2020;6(1):e12005.

36.   Xie B, Shi X, Xing Y, Tang Y*. Associationbetween atherosclerosis and Alzheimer's disease: A systematic review and meta-analysis.Brain Behav. 2020;10(4):e01601.

37.   Qin Q, Tang Y*, Dou X, Qu Y, Xing Y, Yang J,Chu T, Liu Y, Jia J. Default mode network integrity changes contribute tocognitive deficits in subcortical vascular cognitive impairment, no dementia. Brain Imaging Behav. 2021;15(1):255-265.

38.   Jia J*, Wei C, Chen W, Jia L, Zhou A, Wang F, Tang Y,Xu L. Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild toModerate Alzheimer's Disease. J Alzheimers Dis. 2020. doi: 10.3233/JAD-190940.

39.   Jia L, Fu Y, Shen L, Zhang H, Zhu M, Qiu Q, Wang Q, Yan X,Kong C, Hao J, Wei C, Tang Y, Qin W, Li Y, Wang F, Guo D, Zhou A,Zuo X, Yu Y, Li D, Zhao L, Jin H, Jia J*. PSEN1, PSEN2, and APP mutations in404 Chinese pedigrees with familial Alzheimer's disease. Alzheimers Dement.2020;16(1):178-191.

40.   Tang Y*, Liu Y, Li D, Guo D, Xing Y*. A novel mutation in the CYP27A1 gene in afamily with cerebrotendinous xanthomatosis. Int J Neurosci. 2020; 1-4.

41.   Quan M, Zhao T, Tang Y, Luo P, Wang W, Qin Q,Li T, Wang Q, Fang J, Jia J*. Effects of gene mutation and disease progressionon representative neural circuits in familial Alzheimer's disease. AlzheimersRes Ther. 2020;12(1):14.

42.   Wang H, Fan Z, Shi C, Xiong L, Zhang H, Li T, Sun Y, Guo Q, TianY, Qu Q, Zhang N, Cheng Z, Wu L, Wu D, Han Z, Tian J, Xie H, Tan S, Gao J, LuoB, Pan X, Peng G, Qin B, Tang Y, Wang K, Wang T, Zhang J, Zhao Q,Gauthier S, Yu X*. Consensus statement on the neurocognitive outcomes for earlydetection of mild cognitive impairment and Alzheimer dementia from the ChineseNeuropsychological Normative (CN-NORM) Project. Journal of global health.2019; 9(2): 020320

43.   Shi X, Xie B, Xing Y, Tang Y*. Plasma Clusterinas a Potential Biomarker for Alzheimer's Disease-A Systematic Review and Meta-analysis.Curr Alzheimer Res. 2019;16(11):1018-1027.

44.   Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, Tang Y,Qin Q, Wang F, Qiao Y, Shi S, Wang YJ, Du Y, Zhang J, Zhang J, Luo B, Qu Q,Zhou C, Gauthier S, Jia J*; Group for the Project of Dementia Situation in China.Dementia in China: epidemiology, clinical management, and research advances. LancetNeurol. 2020 Jan;19(1):81-92.

45.   Shen L, Qin W, Wu L, Zhou A, Tang Y, Wang Q,Jia L, Jia J*. Two novel presenilin-1 mutations (I249L and P433S) in early onsetChinese Alzheimer's pedigrees and their functional characterization. BiochemBiophys Res Commun. 2019;516(1):264-269.

46.   Tang Y#*, Xing Y#, Zhu Z#, He Y, Li F, Yang J, Liu Q, Li F,Teipel SJ, Zhao G*, Jia J*. The effects of 7-week cognitive training in patientswith vascular cognitive impairment, no dementia (the Cog-VACCINE study): Arandomized controlled trial. AlzheimersDement. 2019;15(5):605-614.

47.   LiuZ*, Jiao L, Qiu Z, Da Y, Tang Y,Lin Y, Li D, Huang J, Kang X, Dong H*. Clinical characteristics of patientswith paraneoplastic myelopathy.  J Neuroimmunol. 2019 ;330:136-142.

48.   Tang Y*, Qin Q*, Xing Y, Guo D, Di L, Jia J. AARS2 leukoencephalopathy:a new variant of mitochondrial encephalomyopathy. Mol Genet Genomic Med. 2019; 7(4):e00582.

49.   BabulalGM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-FuchsA, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-AndersonP, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, ForteaJ, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R,Kilborn K, Lanctôt KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME,Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS,Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C,Melo van Lent D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H, O'Bryant SE*;International Society to Advance Alzheimer's Research and Treatment,Alzheimer's Association. Perspectives on ethnic and racial disparities inAlzheimer's disease and related dementias: Update and areas of immediate need. Alzheimers Dement. 2019;15(2):292-312.

50.   DuX#, Ji Y#, Chen T*, Tang Y, HanB. Can working memory capacity be expanded by boosting working memory updatingefficiency in older adults? Psychologyand Aging. 2018;33(8):1134-1151. (IF 2.608)

51.   JiaJ*, Wei C, Chen S, Li F, Tang Y,Qin W, Shi L, Gong M, Xu H, Li F, He J, Song H, Yang S, Zhou A, Wang F, Zuo X,Chu C, Liang J, Jia L, Gauthier S. Efficacy and safety of the compound Chinese medicineSaiLuoTong in vascular dementia: A randomized clinical trial. Alzheimers Dement (N Y): TRCI. 2018; 4:108-117.

52.   Tang Y*, Lutz MW, Xing Y. A systems-basedmodel of Alzheimer's disease. AlzheimersDement. 2019;15(1):168-171.

53.   HaydenKM*, Inouye SK, Cunningham C, Jones RN, Avidan MS, Davis D, Kuchel GA, Tang Y, Khachaturian AS. Reducethe burden of dementia now. AlzheimersDement. 2018;14(7):845-847.

54.   KhachaturianAS*, Hayden KM, Mielke MM, Tang Y,Lutz MW, Gold M, Kukull WA, Mohs R, Gauthier S, Molinuevo JL, Zetterberg H,Khachaturian ZS. New thinking about thinking, part two. Theoretical articlesfor Alzheimer's & Dementia. AlzheimersDement. 2018;14(6):703-706.

55.   Li J, Wu L, TangY, Zhou A, Wang F, Xing Y, Jia J*. Differentiation of neuropsychologicalfeatures between posterior cortical atrophy and early onset Alzheimer'sdisease. BMC Neurol. 2018;18(1):65.

56.   Khachaturian AS#*, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gustafson DR,Kukull WA, Mohs R, Khachaturian ZS. Future prospects and challenges for Alzheimer'sdisease drug development in the era of the NIA-AA Research Framework. Alzheimers Dement. 2018;14(4):532-534.

57.   Wang Z, Qin W, Wei CB, Tang Y, Zhao LN, Jin HM, Li Y, Wang Q, Luan XQ, He JC, Jia J*.The microRNA-1908 up-regulation in the peripheral blood cells impairs amyloidclearance by targeting ApoE. Int JGeriatr Psychiatry. 2018;33(7):980-986.

58.   Jia J#*, Wei C*, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, Zhou A, Zuo X,Wu L, Han Y, Han Y, Huang L, Wang Q, Li D, Chu C, Shi L, Gong M, Du Y, Zhang J,Zhang J, Zhou C, Lv J, Lv Y, Xie H, Ji Y, Li F, Yu E, Luo B, Wang Y, Yang S, QuQ, Guo Q, Liang F, Zhang J, Tan L, Shen L, Zhang K, Zhang J, Peng D, Tang M, LvP, Fang B, Chu L, Jia L, Gauthier S. The cost of Alzheimer's disease in Chinaand re-estimation of costs worldwide. AlzheimersDement. 2018;14(4):483-491

59.   Zhang Y, Guo D, Tang Y*. Autonomic dysfunction in a patient with X-linkedadrenoleukodystrophy. Int J Neurosci.  2017; 28:1-2

60.   Liu Q#, Zhu Z#, Teipel SJ, Yang J, Xing Y, Tang Y*, Jia J* White MatterDamage in the Cholinergic System Contributes to Cognitive Impairment inSubcortical Vascular Cognitive Impairment, No Dementia. Front. Aging Neurosci. 2017; 9: 47.

61.   Jia J#*, Gauthier S, Pallotta S, Ji Y, Wei W, XiaoS, Peng D, Guo Q, Wu L, Chen S, Kuang W, Zhang J, Wei C, Tang Y. Consensus-based recommendations for the managementof rapid cognitive decline due to Alzheimer's disease. Alzheimers Dement. 2017;13(5):592-597.

62.   Dong J, Qin W, Wei C, Tang Y, Wang Q, Jia J*. A Novel PSEN1 K311R Mutation Discoveredin Chinese Families with Late-Onset Alzheimer's Disease Affects Amyloid-βProduction and Tau Phosphorylation.  J Alzheimers Dis. 2017;57(2):613-623.

63.   Jia J#*, Wei C#, Jia L, Tang Y, Liang J, Zhou A, Li F, Shi L, Doody RS. Efficacy andSafety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: ARandomized Controlled Trial. J AlzheimersDis. 2017;56(4):1495-1504.

64.   Xing Y#, TangY#, Zhao L, Wang Q, Qin W, Ji X, Zhang J, Jia J*. Associations betweenplasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson'sdisease dementia. J Neurol Sci. 2016;370:82-87.

65.   Tang Y#*, Zhu Z#, Liu Q, Li F, Yang J, Li F, Xing Y,Jia J*. The efficacy of Cognitive training in patients with VAsCular CognitiveImpairment, No dEmentia (the Cog-VACCINE study): study protocol for a randomizedcontrolled trial. Trials. 2016;17(1):392.

66.   Xing Y#, TangY#, Zhao L, Wang Q, Qin W, Zhang J, Jia J*. Plasma ceramides andneuropsychiatric symptoms of Alzheimer’s disease. J Alzheimers Dis. 2016; 52(3):1029-35.

67.   Jia J*, Zuo X, Jia XF, Chu C, Wu L, Zhou A, Wei C, Tang Y, Li D, Qin W, Song H, MaQ, Li J, Sun Y, Min B, Xue S, Xu E, Yuan Q, Wang M, Huang X, Fan C, Liu J, RenY, Jia Q, Wang Q, Jiao L, Xing Y, Wu X; China Cognition and Aging Study (COAST)Group. Diagnosis and treatment of dementia in neurology outpatient departmentsof general hospitals in China. AlzheimersDement. 2016; 12(4):446-53.

68.   Xing Y, TangY, Jia J*. Sex Differences in Neuropsychiatric Symptoms of Alzheimer'sDisease: The Modifying Effect of Apolipoprotein E ε4 Status. Behav Neurol. 2015;2015:275256. doi:10.1155/2015/275256.

69.   Tang Y*#, Wang X#, Jia J#. Mercury poisoningpresenting as sporadic creutzfeldt-jakob disease: a case report. Ann Intern Med. 2015;162(6):462-3.

70.   Lu H, Wang XB, TangY*. Subdural hematoma associated with high altitude. Chin Med J (Engl). 2015;128(3):407-8.

71.   Qin W, Jia X, Wang F, Zuo X, Wu L, Zhou A, Li D,Min B, Wei C, Tang Y, Xing Y,Dong X, Wang Q, Gao Y, Li Y, Jia J*. Elevated plasma angiogenesis factors inAlzheimer's disease. J Alzheimers Dis.2015;45(1):245-52.

72.   Liang J, Li F, Wei C, Song H, Wu L, Tang Y, Jia J*. Rationale andDesign of a Multicenter, Phase 2 Clinical Trial to Investigate the Efficacy ofTraditional Chinese Medicine SaiLuoTong in Vascular Dementia. J StrokeCerebrovasc Dis. 2014; 23(10):2626-34.

73.   Jia J*, Zhou A, Wei C, Jia X, Wang F, Li F, Wu X,Mok V, Gauthier S, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P,Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P,Li Y, Qiao Y, Tang Y, Lv J,Dong X. The prevalence of mild cognitive impairment and its etiological subtypesin elderly Chinese. Alzheimers Dement.2014;10(4):439-47.

74.   Jia J*, Wang F, Wei C, Zhou A, Jia X, Li F, Tang M,Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, QinW, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. Theprevalence of dementia in urban and rural areas of China. Alzheimers Dement. 2014;10(1):1-9

75.   Jia J*, Wang F, Yuan Q, Qin W, Tang Y, Zuo XM, Han Y. Progresses on Genetics of PredementiaPhase of Alzheimer's Disease. Prog BiochemBiophys. 2012;39(8), 698-702.

76.   Xing Y, Wei C, Chu C, Zhou A, Li F, Wu L, Song H,Zuo X, Wang F, Qin W, Li D, Tang Y,Jia XF, Jia J*. Stage-specific gender differences in cognitive and neuropsychiatricmanifestations of vascular dementia. Am JAlzheimers Dis Other Demen. 2012;27(6):433-8.

77.   Tang Y#, Xing Y#, Lin MT, Zhang J, Jia J*.Hashimoto's encephalopathy cases: Chinese experience. BMC Neurol. 2012; 24;12:60.

78.   Dong HQ#, Liu Z#, Tang Y, Lu Y, Wang Q, Jia J*. Recurrent Fisher-Bickerstaff syndrome:report of a Chinese case. Chin Med J(Engl). 2011;124(17):2786-8.

79.   Tang Y#, Chu C#, Lin MT, Wei G, Zhang X, Da Y,Huang H, Jia J*. Hashimoto's encephalopathy mimicking spinocerebellar ataxia. J Neurol. 2011;258(9):1705-7.

80.   Huang H#*, Chen J, Lin T, Wang T, Tang Y, Dong Y, Wang J. Epoxyeicosatrienoicacids--novel mechanism and pharmacological therapy of chronic renocardiacsyndrome. Med Hypotheses.2011;76(4):550-2.

81.   Tang Y, Ding Y, Li CJ, Wang XB*, Jia J. longitudinallesion of the spinal cord in a patient with Vogt-Koyanagi-Harada disease. J Neurol Neurosurg Psychiatry 2010;81:941-942

82.   Xu EH#, TangY, Li D, Jia J*. Polymorphism of HD and UCHL-1 genes in Huntington'sdisease. J Clin Neurosci. 2009, 16(11):1473-7.

83.   Li Y#, Liu W#, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, PrzedborskiS, Beal MF, Burke RE, Li C*.Mutant hR1441G LRRK2 BACTransgenic Mice Recapitulate Cardinal Features of Parkinson’s Disease. Nature Neuroscience 2009, 12(7):826-8.

84.   Tang Y#, Huang Y#, Shen W, Liu DP*, Liu G, Wang Z,Tang XB, Liang CC. Cluster specific regulation pattern of upstream regulatoryelements in human α- and β-globin gene clusters. Exp. Cell Res. 2008, 314(1):115-22

85.   Wei YJ#*, TangY#, Cui CJ#, Zhang H, Liu XN, Zhang H, Hu SS*. Expression pattern ofdog stromal cell derived factor-1 (SDF-1) and implications in ischemic myocardium.Cytokine 2007, 40(1):52-9

86.   Tang Y, Wang Z, Huang Y, Liu G, Shen W, Tang XB, Feng DX, Liu DP*, Liang CC, GeneOrder in Human alpha-globin Locus is Required for Their Temporal Specific Expressions.Genes Cells. 2006,11(2):123-31.

87.   Tang Y, Liu DP*, Liang CC. Further understandingof the beta-globin locus regulation at the molecular level: looping or linkingmodels? Genes Cells. 2002, 7(9): 889-900.

88.    Tang XB, Feng DX, Di LJ, Huang Y, Fu XH, Liu G, TangY, Liu DP*, Liang CC. HS-48 alone has no enhancement role on theexpression of human alpha-globin gene cluster. Blood Cells Mol Dis. 2007, 38(1):32-6

89.    Shen W, Huang Y, Tang Y, Liu DP*, LiangCC. A General Method to Modify BACs to Generate Large Recombinant DNA FragmentsMol. Biotechnology.2005, 31: 181-186

90.   Huang Y, Liu DP*, Feng DX, Wu M, Shen W, TangY, Tang XB, Liang CC. No existence of translocus balancer to coordinatethe expression and regulation of human hemoglobin genes in transgenic mice study.Int J Biochem Cell Biol. 2004, 36(7): 1261-5.

二、第一/通讯作者中文文章23篇

1.  中华医学会神经病学分会痴呆与认知障碍学组, 认知数字疗法中国专家共识写作组，通讯作者，认知数字疗法中国专家共识（2023）. 中华医学杂志, 2023,103(9) : 640-647.

2.   秦琪,夏心怡,唐毅.神经病学临床案例库的建立与应用研究[J].中国医刊,2023,58(02):229-232.

3.   认知训练中国指南写作组,中国医师协会神经内科医师分会,通讯作者:唐毅.认知训练中国指南(2022年版)[J].中华医学杂志,2022,102(37):2918-2925.

4.   秦琪,唐毅,曲怡达,周爱红,丁建平,尹筠思,刘勇,贾建平.利用弥散张量成像技术观察小血管病所致非痴呆型血管性认知障碍患者白质结构损害与认知下降的关系[J].首都医科大学学报,2021,42(03):373-384.

5.   邢怡，唐毅. 认知训练早期干预痴呆的研究进展[J]. 中国神经免疫学和神经病学杂志,2020,27(6):358-359.

6.   石新蕊,王治斌,唐毅.听觉信息整合障碍与阿尔茨海默病[J].中国医学前沿杂志（电子版）,2020,12(10):8-12.

7.   认知训练中国专家共识写作组, 中国医师协会神经内科医师分会认知障碍疾病专业委员会，唐毅朱祖德执笔. 认知训练中国专家共识[J].中华医学杂志,2019,99( 1 ): 4-8.

8.   中国痴呆与认知障碍诊治指南写作组,中国医师协会神经内科医师分会认知障碍疾病专业委员会，贾建平，唐毅执笔.2018中国痴呆与认知障碍诊治指南(六):阿尔茨海默病痴呆前阶段[J].中华医学杂志,2018,98(19):1457-1460.

9.   中国痴呆与认知障碍诊治指南写作组,中国医师协会神经内科医师分会认知障碍疾病专业委员会，唐毅，吕佩源执笔.2018中国痴呆与认知障碍诊治指南(七):阿尔茨海默病的危险因素及其干预[J].中华医学杂志,2018,98(19):1461-1466.

10.    楚长彪,唐毅. 医学专业英语运用能力培养的探索[J]. 中国医刊,2018,53(07):824-826.

11.    唐毅,杨坚炜,郭冬梅,邱琼琼,楚长彪. 免疫介导性帕金森综合征四例报告并文献复习[J]. 中国医刊,2018,53(06):665-668.

12.    唐毅. 阿尔茨海默病诊断标准：从临床诊断到病理生理诊断[J].    山东大学学报,2017,55(10):14-20.

13.    唐毅,杨坚炜,郭冬梅,李丹,赵丽娜,李洁颖,贾建平*. 皮质基底节综合征四例临床分析[J]. 中华医学杂志,2017,97(17):1343-1345.

14.    唐毅,杨坚炜,郭冬梅,楚长彪. 舞蹈病-棘红细胞增多症4例临床分析及文献复习[J]. 中国医刊,2017,52(05):81-83.

15.    唐毅,邢怡,秦伟,贾建平. 阿尔茨海默病患者性腺轴激素水平与认知功能的相关性及载脂蛋白E基因的调节作用[J]. 中华老年心脑血管病杂志,2017,19(04):340-344.

16.    唐毅,邢怡,张津等.桥本脑病患者的临床特征和预后随访观察[J].中华医学杂志,2014,94(9):670-673.

17.    唐毅,陆慧,王向波等.以周围神经损害为主要表现的汞中毒患者9例分析[J].疑难病杂志,2014,13(2):139-142.

18.    唐毅,楚长彪.医学英语教学的特点分析和策略探讨[J].中国医药导报,2014,11(4):122-124.

19.    唐毅,王向波.小柳原田病合并脊髓损害的临床研究并文献复习[J].中国医刊,2014,49(1):44-46.

20.    唐毅,纪笑娟,邢怡，左秀美, 周爱红, 贾建平*.帕金森病痴呆与阿尔茨海默病的认知和精神行为症状比较[J].中华医学杂志,2013,93(31):2459-2462.

21.    唐毅,贾建平. tau蛋白和自噬在PS-1基因突变发病机制中的作用[J]. 中国现代神经疾病杂志,2010,02:261-264.

22.    唐毅,贾建平. 肌张力障碍的治疗进展[J].中风与神经疾病杂志,2007,05:629-632.

23.    唐毅,魏英杰,胡盛寿等.SDF-1-CXCR4轴与缺血性心脏病的干细胞治疗[J].基础医学与临床,2006,26(8):915-921.